China’s Innovent works with Adimab in second bispecific deal this month

China flag
China flag

Suzhou-based biotech Innovent Biologics is expanding ties to identify and develop monoclonal and bispecific antibodies by enhancing a collaboration pact with Adimab to generate IgGs for multiple targets--marking the second such announcement this month.

Innovent will identify the targets and develop any potential candidates. It will also hold global rights, according to a statement from the company. Financial terms were not disclosed.

Earlier this month, Innovent agreed to a potential $120 million partnership deal with Shanghai-based biotech startup EpimAb Biotherapeutics on bispecific antibodies that builds on a landmark deal in the same space reached with Eli Lilly ($LLY) last year and that has since expanded.


Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

Innovent will buy the rights to EpimAb’s Fabs-In-Tandem Immunoglobulin, dubbed FIT-Ig, a proprietary platform to develop multiple bispecific antibodies for China. In doing so, it will and obtain the rights to out-license outside of the region in return for an upfront payment, milestones and royalties.

Innovent and Adimab initially began work three years ago on a single target for Adimab to develop into a drug candidate. Under that deal, Innovent held China rights to any therapy developed, while Adimab kept global rights. Further details of that deal were also not disclosed.

"We know from our previous projects that Adimab's reputation as the leading protein engineering company in the industry is well deserved. An antibody that came out of our relationship with Adimab is part of our recent partnership with Eli Lilly and Company," Michael Yu, CEO and co-founder of Innovent, said in a statement.

"Gaining broader access to Adimab was very important to achieving our long-term goals, so we are very pleased to have expanded our relationship."

Innovent lists 10 antibodies in development covering indications from ophthalmology to oncology to inflammatory diseases.

Adimab uses its antibody discovery and optimization platform and custom antibody libraries to work with major drug companies, including Merck ($MRK), Novartis ($NVS) and Eli Lilly, among others, as well as academic researchers.

- here's the release

Related Articles:
China's Innovent in $120M bispecifics partnership with EpimAb
Lilly and China's Innovent Biologics tie up on cancer drug candidates with $56M upfront


Suggested Articles

It’s a familiar scene in the race onto China’s national reimbursement list: Drugmakers cut prices by an average 60.7% to win coverage.

After a longer follow-up of 25 months, Alunbrig cut the risk of disease progression by 51% compared with Xalkori in ALK inhibitor-naïve NSCLC.

Novartis pivots Shanghai R&D from discovery to development. BeiGene nabs FDA nod for BTK inhibitor Brukinsa. FDA clears Shionogi's antibiotic Fetroja.